Abstract: Lipophilicity is a key physicochemical property that plays a critical role in determining ADMET properties and the overall suitability of drug candidates. Increasing evidence suggests that control of physicochemical properties like lipophilicity, within a defined optimal range, can improve compound quality and the likelihood of therapeutic success. Particular attention to this optimum region of lipophilicity as well as monitoring of lipophilic efficiency indices such as LLE and LELP may contribute significantly to the overall quality of candidate drugs throughout drug development.
INTRODUCTION
The overall drug development process is far from ideal, as only a small percentage (roughly 10%) of compounds selected for clinical trials make it to the marketplace as effective therapeutic agents [1] . This is due, in part, to the idea that greater in vitro potency will lead to a more effective therapeutic, which is often embedded in early drug discovery schemes. To be successful, drug development requires not only optimization of specific and potent recognition by its pharmacodynamic targets, but also efficient delivery to these target sites-a drug must be able to reach the biophase, crossing several biomembranes by passive and/or transporter mediated uptake, in order to elicit an in vivo response. Important biopharmaceutical properties that facilitate a drug's entry into the body and across various cellular barriers include its solubility, stability, permeability, and first pass effect, as well as pharmacokinetic properties (clearance rate, biological half-life, and volume of distribution among others).
Recent advances in high-throughput screening, combinatorial chemistry, and molecular modeling, and high-throughput screening have shifted the bottleneck of drug discovery to potency optimization rather than hit and lead discovery [2] . However, lead discovery remains a challenging endeavor since the starting points of lead optimization usually determine the delivered product.
Drugs can be designed for more effective delivery if physicochemical principles are given careful consideration during their development. Lipinski's rule of 5 describes the molecular properties important for effective drug delivery and pharmacokinetics in the human body. According to this rule, an orally active *Address correspondence to this author at the Department of Basic Sciences, The Commonwealth Medical College, 525 Pine Street, Scranton, PA 18509, USA; Tel: 570-504-9629; Fax: 570-504-9636; E-mail: splaney@tcmedc.org drug should not have more than 5 hydrogen bond donors (nitrogen or oxygen atoms with one or more hydrogen atoms); 10 hydrogen bond acceptors (nitrogen or oxygen atoms); 500 daltons (Da) molecular mass; and a 5 octanol-water partition coefficient log P [3] . In general, one exception to the above rule is allowed. Because it constitutes the most informative and successful property in determining ADMET properties and the overall suitability of drug candidates, lipophilicity has emerged as a critical parameter in drug discovery and design [4, 5] .
This short communication will focus on understanding lipophilicity and discuss the importance of monitoring lipophilic efficiency indices such as LLE and LELP which may contribute significantly to the overall quality of candidate drugs at different stages of discovery.
LIPOPHILICITY
Lipophilicity, which refers to the ability of a compound to dissolve in fats, oils, lipids, and non-polar solvents such as hexane or toluene, has long been recognized as an important factor for a drug's successful passage through clinical development and on to the marketplace. A calculated log P (clog P) is routinely used as an assessment of lipophilicity in vivo, which reflects the key event of molecular desolvation in transfer from aqueous phases to cell membranes and to protein binding sites. Given the value and influence of lipophilicity on the drug discovery and design process and its evidenced role as a predictor of eventual compound success, an understanding of lipophilicity and how to modulate it are essential for the development of a successful therapeutic compound.
ADMET AND LIPOPHILICITY

Lipophilicity
contributes to the ADMET characteristics of drugs (for review see [6] ), by contributing to their solubility and permeability through membranes [2, 7] ; potency [8] , selectivity, and promiscuity [4] ; impacting their metabolism and pharmacokinetics [9] ; and also affecting their pharmacodynamic and toxicological profile [10] . A common finding when comparing marketed oral drugs with compounds in earlier stages of development is that high lipophilicity (>5) frequently leads to compounds with rapid metabolic turnover [11] , low solubility, and poor absorption [3] . However, if lipophilicity is too high, there is an increased likelihood of in vitro receptor promiscuity [4, [12] [13] [14] and in vivo toxicity [10, 15, 16] , as well as poor solubility and metabolic clearance. Similarly, if lipophilicity is too low, a drug will generally display poor ADMET properties.
Although the average lipophilicity value has changed little for oral drugs approved since 1983 (2.6), there is a noted trend of increased lipophilicity as candidate molecules progress through Phase I, II, and III clinical trials. This undesired shift in log P is noted as a major factor for the well documented inflation of physicochemical properties of drugs [4, 17] and is evident in recent medicinal chemistry practice as demonstrated by Walters et al. [18] . According to Lipinski, a limit of log P < 5 is a desirable lipophilicity range for compounds reaching Phase II clinical trials [3] ; however, Gleeson has suggested that compounds with log P < 4 (and a molecular weight < 400) stand a much higher chance of success against a comprehensive set of ADMET parameters [9] . A recent review of the literature, indeed suggests that the optimum region of lipophilicity lies within a narrow range of log P or D between ~ 1 and 3 to ensure optimal physiochemical properties [6, 19] (Table 1 ).
MEASURING LIPOPHILICITY
Lipophilicity reflects the net result of all intermolecular forces involving a solute and the two Renal Clearance better [50, 51] Clearance <3 MW dependent [52] better [53] Toxicity > 3 PSA dependent [9] Promiscuity > 3 PSA dependent [54] >2 [13] hERG inhibition less Ionization dependent [55] CYP inhibition less Ionization/MW dependent [8, 35] DIPL Sum log P2 and pKa > 90 [17, 56] phases between which it partitions and is determined experimentally as partition coefficients (log P) or as distribution coefficients (log D) wherein Log P describes the partition equilibrium of an un-ionized solute between water and an immiscible organic solvent, while log D determines the ratio of the sum of the concentrations of all forms of the compound (pHdependent mixture of ionized plus un-ionized forms) in each of the two phases [5] . The accurate and efficient measurement of lipophilicity is an important requirement in drug design; however, in practice, the calculated value (clog P) is often used instead of the measured log P. clog P values used for screening virtual libraries are often inaccurate, leading to imprecise results that can cause potentially promising compounds to be discarded and /or potentially flawed compounds to move forward [20] . Thus, log P should be experimentally evaluated for a representative set of compounds in order to accurately predict log P for a given chemical series. The use of confidence in log P prediction would allow higher resolution and discrimination with regard to selection of reliable and nonreliable predictions, thus increasing design efficiency.
Lipophilicity Indices
Successful drug discovery not only requires the optimization of physicochemical parameters but also more complex parameters related to toxicity and bioavailability. Recent developments in the field of drug discovery have raised some serious questions related to usefulness of physicochemical properties from lead discovery to drug candidate. This has led to the emergence of the idea of using LE (binding energy/non-hydrogen atoms) as a useful guide to optimize fragment and lead selection in the discovery process. Several useful efficiency indices including ligand efficiency (LE), ligand lipophilic efficiency (LLE) and ligand-efficiencydependent lipophilicity (LELP) have been developed that can incorporate multiple physiochemical parameters for drug-likeness assessment throughout the drug discovery process. Unlike LLE and LELP, LE does not consider lipophilicity, but is essential in calculating the former indices.
Ligand Efficiency (LE)
Ligand efficiency (LE), which relates to efficiency of potency per heavy atom in a ligand, is a wellestablished metric commonly used to assess affinity of compounds for a target (Figure 1) . It measures compounds based on normalized potency with respect to the molecular size [21] and allows comparison of potency among compounds within a wide range of molecular size. LE is a particularly important parameter in fragment drug design as it gives priorities to small molecules with relatively lower potency rather than larger, higher potency molecules [22, 23] . However, LE has often been subject to criticism, as it does not completely eliminate size bias [24] [25] [26] and fails to take lipophilicity into account. Thus, it could lead to selection of molecules with acceptable potency, but poorer ADMET properties. According to Hopkins et al, LE can be defined numerically as the quotient of G and the number of non-hydrogen atoms of the compound using the following equation: LE = ( G)/N, where G = -RTlnKi, N is the number of non-hydrogen atoms, and the units of LE are kcal/mol per non-hydrogen atom [21] . 
Ligand Lipophilicity Efficiency (LLE)
Ligand lipophilicity efficiency (LLE or LipE [27] ) is a ligand efficiency index that was first proposed by Leeson and Springthrope [4] . LLE provides a straightforward and meaningful way to evaluate the quality of research compounds, linking potency and lipophilicity in an attempt to estimate drug-likeness. LLE attempts to maximize the minimally acceptable lipophilcity per unit of in vitro potency or more simply, to improve potency, while maintaining low lipophilicity [4] . LLE is defined as the difference of log P (or log D) and the negative logarithm of a potency measure (pKd, pKi or pEC50) (Figure 1 ) [28] . In practice, the calculated value clog P is mostly used instead of measured log P along with the most relevant in vitro potency predicting in vivo efficacy. It is important to note that calculated and measured lipophilicity often do not agree [6] and that log D is more suitable for charged compounds [29, 30] . For a 1 nM inhibitor with a log P = 3, the LLE = 6, while for a 10 nM inhibitor with a log P = 3, LLE = 5, and the optimal LLE scores range from ~5-7 or greater based on an average oral drug clogP ~2.5 and potency in the range of ~1-10nM [4, 31] . LLE has gained popularity over the last several years a straightforward and meaningful way to control lipophilicity. The application of LLE in drug optimization is highlighted by several recent examples, including the design of a potent cyclin-dependent kinase 2 (CDK2) inhibitor [32, 33] , protein kinase B inhibitor [34] , soluble epoxide hydrolase inhibitors [35] , CB2 agonists [27] , CB2 agonists/CB1 agonists [36] , ATP-competitive Akt inhibitors [37] , dual PI3K/mTOR inhibitors [38] , and HIV non-nucleoside reverse transcriptase inhibitors [39] (for a review see [29, 31] ).
LLE can be used to identify low potency target compounds that are small in size and have low lipophilicity that would otherwise be overlooked. This is advantageous due to the fact that size and lipophilicity are generally inflated during subsequent lead optimization and thus using smaller, less lipophilitic compounds as a starting point is beneficial [28, 40, 41] . However LLE is not size adjusted, thus LLE is less optimal for assessment of compounds with reduced complexity including fragments and other low potency molecules [42] . A recent study assessing LLE and compound quality on drugs and drug candidates at both early and late stages in the drug discovery process demonstrated that while LLE was able to predict compound quality along the discovery path, it was not suitable for fragment-type hits and is less optimal in ADMET and safety related predictions compared to other indices [42] . Given that fragmenttype hits are considered good starting points for lead discovery, this represents a clear limitation to the LLE index at early stages in the drug discovery process.
Ligand Efficiency-Dependent Lipophilicity Index (LELP)
The ligand efficiency-dependent lipophilicity index (LELP) has recently been proposed to combine lipophilicity, molecular size and potency into one composite descriptor [28] , thus overcoming the size limitation of LLE. The concept LELP [28] , defined as the ratio of log P and ligand efficiency (LE), is an efficacy index used for log P values typical in many discovery programs and allows both fragments and lead-like and drug-like compounds to be evaluated [28] .
LELP is negative only when log P is negative and thus the higher the LELP score, the less drug-like the compound [28] . The lower limit of LE is 0.3 and the lipophilicity range is -3< log P <3 which defines a range of optimal LELP scores as -10<LELP<10 [28] . In a retrospective study that evaluated a CNS drug set, LELP could distinguish between marketed drugs over drug candidates. It was also found that candidate drugs with suboptimal LELP value did not proceed far in the development pipeline [43] . More recently, Tarcsay et al., evaluated the performance of LELP on multiple data sets representing different stages of drug discovery, including fragment and HTS hits and leads, development candidates, phase II compounds, and launched drugs [42] . In analyzing the impact LELP on ADME and safety properties as well as binding thermodynamics, they determined that LELP can differentiate drugs from leads and even compounds that entered phase II clinical trials [42] . Thus, this study suggests that monitoring lipophilic efficiency metrics LELP could help to control physiochemical parameters, especially log P or log D, while maintaining compound potency throughout optimization, improving compound quality [42] . However LELP has limitations for compounds with log P < 1, such as natural products.
DISCUSSION
Drug discovery involves identifying lead-compounds and optimizing physicochemical properties through structural modifications to achieve a profile that not only provides the desired efficacy at an acceptable dose, but also minimizes any toxicological liabilities. Despite, numerous improvements in recent years, medicinal chemistry efforts are still often producing compounds that are failing in the drug development process as a result of poor ADMET characteristics. A common trend which has emerged is that there is too heavy a focus in drug discovery on advancing candidate molecules with increased molecular weight (MW) and higher overall lipophilicity due to a focus on enhancing drug potency [31] . It is apparent that a key challenge for successful drug discovery is finding a balance between the constraints on the physicochemical properties of drug candidates and maintaining sufficient potency to provide an efficacious dose. Therefore, the best outcomes in the identification of candidate drugs are likely to come from the effective combination of both a good chemical starting points for lead optimization and careful monitoring of physiochemical parameters during development.
Given the role of lipophilicity in influencing drug potency and ADMET properties, the use of indices such as LE, LLE and LELP is an important objective for lead generation and optimization programs. Use of these indices may help ensure optimal potency, in addition to selecting for and identifying, candidate compounds with appropriate physiochemical characteristics that affect druglikeness downstream. Thus, there is a need for a heightened awareness of the importance of early screening for physicochemical properties, like lipophilicity, via indices that ensure the parallel integration of multiple parameters like potency early into the drug design process.
